Navigation Links
New Engineered Drug Shows Promise in Treating Lymphocytic Leukaemia

A recent research has found that a new type of engineered drug may have the potential to treat chronic lymphocytic leukaemia.

The study by researchers at the Ohio State University Comprehensive Cancer Center was published online in the journal Blood.

The research has established that an engineered drug candidate is promising in treating lymphocytic leukemia in both test tube and early animal tests.

The agent represents a new class of agents called small modular immunopharmaceuticals. This agent, which is called CD37-SMIP, targets a protein called CD37 on the surface of these leukemia cells.

The study shows that the agent can successfully attach to the protein on the leukemia cells and destroy them. It works both by activating the cells' self-destruction and by causing a particular class of immune cells to attack them.

In an animal model, the agent worked uniformly over and above the drug rituximab, now routinely used to treat chronic lymphocytic leukemia (CLL) patients. Rituximab targets a different protein on leukemia cells.

"Our findings have significant implications for the treatment of CLL and related malignancies," says principal investigator John C. Byrd, director of the hematologic malignancies program at Ohio State 's James Cancer Hospital and Solove Research Institute.

Overall, Byrd says, "the findings point out that this could be an effective agent for treating CLL and other malignancies, such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia when they have expression of the CD37 protein."

The laboratory portion of the study used CLL cells from patients, laboratory-grown non-Hodgkin's lymphoma cells and acute lymphocytic leukemia cells.

This research showed that the agent kills leukemia cells directly by triggering their self-destruction through the process of apoptosis.

The study also found that thi s self-destruction happens differently from how other drugs cause apoptosis. Most drugs cause cells to self-destruct by triggering a cell mechanism that requires enzymes called caspases. This new agent, however, works through a mechanism that does not call for caspases.

"This is exciting because it means that this agent may benefit patients who are resistant to other CLL drugs," says co-author Natarajan Muthusamy, a research scientist with Ohio State's Comprehensive Cancer Center. "It also suggests that it might work well in combination with other drugs, as well as alone."

The findings also show that after the agent joins with the cancer cells, it attracts immune cells called natural killer cells, which also devastate the leukemia cells.


Related medicine news :

1. Regulators Object Drug Produced from Genetically Engineered Farm Animals
2. Engineered Tissue Implants benefited Knee Injured patients
3. Indian American have Genetically Engineered Edible Cottonseed
4. USDA Gives Go-Ahead to Market Controversial Genetically Engineered Rice, LL601
5. Xylitol To Be Produced By Genetically Engineered E. Coli
6. Genetic-Engineered Cows Resist Mad Cow Disease
7. Researchers Explore the Effect of Engineered Immune Cells on HIV
8. Tissue Engineered Scaffolding Allows Reproduction of Cartilage Tissue
9. Experimental treatment for Ebola Virus Shows promising results in mice
10. New Prostate Cancer Vaccine Shows Promise
11. Ebola Treatment Shows Promise
Post Your Comments:

(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
Breaking Medicine Technology: